Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks StockAnalyzer regarding RPRX.
I believe the money flow trend will reverse based on nearterm news (if its what we longs anticipate). I appreciate your help in pointing out this aspect of the TA for RPRX, as well as the charts and resistance annotations.
One follow-up question. From your experience, is it normal to see moneyflow trend slow down after substantive news releases from biotech companies......where funds are waiting for the next flow of information to create more buying?
Regards,
Spartex
Hi Tony, Q on RPRX chart
Can you give me your thoughts regarding the chart (TA) of RPRX? I've been long since the $6's, and accumulated more in the 9's and 10's. Company will be releasing some trial results in around a week, which we believe will be consistent with positive Dec. interim results.
Thanks!
Since so many people believe in Provenge, you would think that someone could establish a foundation to fund compassionate use of Provenge for some prostate patients. I realize you need a person with resources and connections to wealthy individuals/foundations to help set up such a fund, but it is a thought that came to my mind. Does compassionate use have to be funded ONLY by the company (DNDN)? Can someone else provide the $$$?
I'm very sorry to hear that DNDN didn't actually go to the market to raise another $80 mil dollars by selling 5 mil shares when the stock was in the $17 dollar range. Would have been a prudent measure (what I was hoping for). So what happened? Did Mitch not listen to his CFO?? I have no idea. I sold have of my position in $21's as a measure of prudence and it paid off. Oh well.
RPRX afterhours
Bio_Pete, what's with these 100 share afterhour trades for RPRX 92 cents above the close?? You also mentioned that these premarket trades above $13 were meaningful for the direction of RPRX stock. Thoughts??
Otherwise, the trend is your friend!
Is RPRX having a stealth rally?
I would call it a stealth accumulation, but it isn't stealth to those of us who own the stock. Between what dewophile, Nerf, rfj and others have stated on this thread, as well as those on RPRX board, there isn't much more to say at this time.
The stock is very undervalued, and it may only be 12 months before they are bought out. I consider that a very short timeline from a biotech point of view.
Regards,
Spartex
Dew, thanks for your earlier reply, and also reference to your Testim results (compared to Androgel) back in Dec 06. I sort of agree with rfj that it makes sense to compare Androxal to the current leader in the field, but it would be nice to also have had a comparison to Testim (but the company is controlling their $$$ carefully) which has better efficacy than Androgel.
rfj's reply back to you here sounds very reasonable to me.
http://www.investorshub.com/boards/replies.asp?msg=15698871
Nerf-- question on RPRX's 10-K regarding competion. I also posted this to dewophile on other board. thanks!
http://www.investorshub.com/boards/read_msg.asp?message_id=19408799
RPRX- Question on 10-K info
On page 9 under "Competition" of RPRX's recent 10-K, for treatment of uterine fibroids and endometriosis is says:
"There are additional companies developing similar progesterone-blocking technology. Asoprisnil, an anti-progestin being developed by TAP Pharmaceuticals in partnership with Schering AG, is currently in Phase III clinical trials."
Question: From previous postings (this one and others) I read that this trial was stopped for Asoprisnil development; is this text within RPRX's 10-K just outdated information?
Thanks for anyones thoughts on this.
Thanks Nerf for your reply. EOM
Bio_pete, yes I read dewophile's nice description of the potential endo issues and precautionary ways that RPRX is approaching Proellex treatment to minimize any risk. I did reply back to dewophile with my thanks. Sorry, I was in too much of a rush with my previous email and it seems like I was overstating my concerns (questions), as much of this has been answered earlier.
Regards, Spartex
Nerf: conversation w/ JP
I have two follow-up questions. When JP said they deal with the endo thickening via a 4/2 cycle (did he mean 4 mo on, and 2 mo off, or just one 1 mo off?). Furthermore, will the endo results be for women on Proellex for the full 6 mo, and is RPRX's strategy to avoid thickening that may be occurring above the cut-off level (safety level) by using the 4 on/1 off approach with Proellex in P3 trials? I think dewophile said that even 6 mo on Proellex didn't caused too much thickening, and RPRX is using a higher 50 mg dose to reduce thichening that may be occurring more so in the 25 mg dose; plus taking the precausious approach of doing a 4 mo followed by holiday to shed the endo before next cycle. Seems like a good plan, and maybe all we need to really move the stock is the FDA meeting in the fall. That is what I believe JP said to you too, so he seems to be speaking sense to me.
thanks!
RPRX Afterhours
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
19:13 $ 13 100
19:13 $ 13 100
19:11 $ 12.09 24,900
19:11 $ 12.09 25,000
18:55 $ 12.09 100
Seems the blocks at $12.09 may have been accumulated during the day and then are reported afterhours. At least I've seen it explained this way with other stocks.
THRM -
Dew, I'm wondering if this Thermage device really just shrinks volume in the person's body (and is it just temporary?). If it was shrinking mass then the question is what part of the body's mass? Most of the human body is made up of water. Hmmmmmmm!
RPRX - Dewophile, thank you very much for those insights based on your professional knowledge in this field. Good luck to you and other RPRX longs, and may the upcoming Proellex safety results support this sentiment.
RPRX Level 2 - what is EDGX doing this morning?
thanks!
rfj, still accumulating? I'd think you would have filled your tank in the $10's and 11's as you are a bargain shopper. But then, RPRX is still a bargain! ;)
Biotech program trading? TA move after pullback? Just comparing RPRX and GNVC movement this morning and both look identical. I own a little GNVC too. Not sure if any other stocks were on this list/movement. Thoughts?
http://finance.yahoo.com/q/bc?t=5d&s=GNVC&l=on&z=m&q=l&c=rprx
I'm not trading. If I do, it would just be 10% of my position around my core holdings. Thanks and best wishes!
Bio_Pete, did you get any cheap shares in 11.2's this a.m.?
Looks like someones interested in buying after the last few days of pause. ;)
Biowatch, are these kinds of letters atypical in DNDN's situation, or are do they occassionally happen for drug approvals? When someone coined the term "battleground" stock for DNDN, they really meant it. I look forward to the evolution of this immunotherapy field one step at a time. ;)
Thanks!
OT: AP Stocks Up Litle Despite Strong Earnings
Thursday April 26, 12:59 pm ET
By Tim Paradis, AP Business Writer
Stocks Advance Moderately After Earnings Reports Fail to Galvanize the Market After Dow Record
so much for spell check or other QC tools at the AP news wire. ;)
http://biz.yahoo.com/ap/070426/wall_street.html?.v=29
Thanks for your thoughts Bio_pete.
Well, it seems we are continuing to get more volume even since your post, within a tight price range. Which I believe indicates bullish "accumulation".
Bio_Pete, do you think the MM's negotiating block trades between themselves, keeping the share price stable? Just noticed around 35k traded with little change in share price. Thoughts from you or others, is this normal for thinly traded stocks?
T.i.a.
Gym, I remember reading a Barron's article 2-3 months ago where one of the analysts said that there was so much liquidity in world stock markets that he expected a market "melt up" to occur sometime during 2007 followed by a good size correction later in the year. It seems like his forecast may play out.
MEDI - Wow, what a deal. Did anyone buy it based on the Goldman Sachs Reuters release on April 12th? I didn't but man buying some May 47.5 or 50 calls, let alone the stock, would have provided some fast money!
GNVC- thanks krenjp for your reply. I agree with what you are saying.
I saw this piece by Feuerstein's mailbox. Seems like his review of GNVC was very cursory and doesn't even look at the other interesting parts of the GNVC pipeline and partners. In some ways, that makes me feel more confident that even folks in the biotech industry may not be following this story closely enough. I mean Feuerstein says, "there's a ton of risk here". Come on, biotechs by design have risk, so why bother just spouting "ton of risk" especially if you can't back up your statement with any facts. I agree with Dew that Feurstein's writing is very soft on analysis and specifics.
Feuerstein's Biotech Mailbag
Page 3
From Mike A. comes a question about GenVec (GNVC - Cramer's Take - Stockpickr - Rating). "I would appreciate your analysis on the potential of GenVec's pancreatic cancer drug TNFerade. They are due to present at ASCO in June."
GenVec is a highly speculative stock. TNFerade (pronounced T-N-F-erade or ten-ef-er-ade? I have no idea) is generating excitement in some corners of the biotech world because gene therapy is sexy and interim data from a phase III trial looks good. However, there's a ton of risk here that won't be cleared up until we get more data on the drug.
Last December, GenVec announced interim survival results from a phase II/III study of TNFerade in patients with locally advanced pancreatic cancer. The data, from the first 51 patients enrolled, showed a 70.5% survival rate in patients given TNFerade plus standard of care at one year, compared to 28% of patients given standard of care alone.
These were encouraging results, but they were derived from a small number of deaths (five and seven in the TNFerade and control arm, respectively) which makes drawing larger conclusions very difficult.
These are the data, I believe, that will be presented in June at the American Society of Clinical Oncology annual meeting, as Mike said. The details will be interesting, but even then, my gut tells me that this TNFerade study in pancreatic cancer is still high-risk.
Pancreatic cancer is really tough to crack; the list of clinical trial failures is long. And TNFerade itself is a bit quirky. The drug uses a benign virus to deliver a therapeutic protein known to be toxic to cancer cells. But in order for TNFerade to work, it must be delivered directly to the tumor. In other words, it can't be injected in the arm or given via an IV. Instead, doctors use a couple of different invasive procedures to get the drug directly into the pancreas, where it then must be activated by radiation.
GenVec: Intriguing story, but I'd tread carefully
http://www.thestreet.com/_yahoo/newsanalysis/biotech/10351640_3.html
REGN up 7.8% on strong volume. $26.29 + 1.85
New 52 week high intraday which should hold into the close.
what does the magic candlestick say today? time to buy? lol
interesting site if you are a trader.
RPRX under accumulation as Cleverox, myself and others have stated. Stock now gets an IBD rating of A- = strong accumulation. Chart looks solid too. Enjoy! ;)
Feuerstein:
He should, however, strengthen his analytical skills. He botches too many stories for someone in his position, IMO. The recent Satraplatin episode is a case in point.
In other words, he needs a few young hot-shot staff to do the DD analytical work to feed into his literary bend so that his stories are more grounded. ;)
PreciousLife: Somehow your intended link didn't post; only your definition of "incomprehensible".
Back to my dark chocolate and red wine. ;)
Genisi: Wanted to say "thanks" the other day back to you for your quick summary of RPRX CEO's presentation on Thurs.
Regards,
Spartex
Someone was dumping 40k shares or more into the close today, and it appears the MM just lapped them up without dropping the price more than a few cents before moving back up to 11.18.
Bladerunner: Did Dr Garren become a bear on GNVC?
I heard from the YMB that he was once a bull and is now a bear on the company, and that there may be some issues going on with his views being biased. thoughts?
T.i.a.
They didn't mention any contribution to increased cancer due to pollution (air, water, other industrial exposures) for the increasingly industrialized nations such as China. Not sure if that would being a significant portion compared to smoking.
Good question: DNDN effect. I am also seeing new 52wk highs in IMMU and especially IMGN on very high volume today. GNVC was yesterday's big mover. It looks like it may involve inflows from both hedge funds and institutions imo. And of course those short may be covering with this upward movement.
I remember watching David Miller on CNBC near the last day of trading (Dec 06) where he listed DNDN panel review/FDA decision as one of his biggest biotech industry influencing events for 2007. Now if we only put a bunch of money (or bought calls) in a basket of these immunotherapy stocks on the cheap during the late Feb-early Mar 07 market correction, we'd be sitting happy! :)
I would then call this product Deleve. To reduce those elevated lines. LOL.
Rats! I missed accumulating DYAX and GNVC. :(
MEDI now trading in pre-market above 41 and 6 mil vol. Wow!
MedImmune up as sources say Goldman hired
Thu Apr 12, 2007 7:19am ET
NEW YORK (Reuters) - Shares of MedImmune Inc. (MEDI.O: Quote, Profile , Research) rose 3 percent before the bell on Thursday after sources told Reuters the biotechnology company had hired Goldman Sachs to help with a possible sale of the company.
In consolidated electronic trading ahead of the opening bell, the stock was up $1.26 at $39 after closing Wednesday at $37.84 on Nasdaq.
Based on Wednesday's closing price, the company has a market capitalization of about $8.8 billion. Its stock has not traded above $39 since August 2003.
http://today.reuters.com/news/articleinvesting.aspx?type=hotStocksNews&storyID=2007-04-12T111946...
RPRX: Thanks dewophile and rfj for your professional thoughts on potential Proellex safety issues. Looking forward to tomorrow's RPRX presentation.